Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: 2 - Caught on Camera

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch

Health care giant Johnson Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter financial results are reported before market open Tuesday.

Benzinga

Options Corner: Despite Political Woes, Kenvue Can Still Make Tylenol Great Again

Amid a contentious political environment, consumer pharmaceutical firm Kenvue Inc (NYSE:KVUE) finds itself under a harsh spotlight. Specifically, its popular drug Tylenol has attracted the ire of the White House. Late last month, President Donald Trump stated on Truth Social that pregnant women shouldn't use Tylenol unless absolutely necessary. With…

Benzinga

Smoke from Wildfires Chokes Austin: What Locals Are Breathing Tonight

Wildfire smoke blankets Austin, with haze from local and distant blazes prompting health alerts and raising questions about the city's fire readiness.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Quadruple murder at Austin yogurt shop was one of city’s most infamous cold cases. 30 years later police have a suspect

Serial killer Robert Eugene Brashers, who died by suicide in 1999, committed at least seven murders across multiple states between 1990 and 1998, prior to the Austin yogurt shop killings

The Independent UK

As Trump Takes Aim at Tylenol, Should You Buy, Sell, or Hold Parent Company Kenvue Stock’s Here?

Kenvue stock is trailing the broader markets by a wide margin in 2025 due to regulatory concerns over its flagship Tylenol product.

Barchart

Kenvue Surges Over 2% Pre-Market Despite Trump Administration's Autism Warning

Kenvue Inc. (NYSE:KVUE) saw its stock rise by 2.61% to $17.69 in pre-market trading on Wednesday, despite concerns stirred by President Trump's controversial comments about acetaminophen potentially being linked to autism.

Benzinga

What's Going On With Kenvue Stock Tuesday?

Kenvue Inc. (NYSE:KVUE) shares are trading higher Tuesday despite President Donald Trump saying the Food and Drug Administration will notify physicians that use of acetaminophen or Tylenol during pregnancy could be associated with increase risk of autism.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Jim Cramer Says Trump Is Creating 'A Nightmare' For Kenvue As President Links Tylenol With Autism

CNBC’s Jim Cramer warned Tuesday that President Donald Trump is creating a “nightmare of potential litigation” for consumer health giant Kenvue Inc. (NYSE:KVUE), sending the company's stock tumbling.

Benzinga

Nvidia, Kenvue, Rivian, MicroCloud Hologram And Opendoor: Why These 5 Stocks Are On Investors' Radars Today

U.S. stocks closed higher on Monday, with the Dow Jones Industrial Average edging up 0.14% to 46,381.54. The SP 500 added 0.4% to finish at 6,693.75, while the Nasdaq climbed 0.7% to 22,788.98.These are the top stocks that gained the attention of retail traders and investors through the day: Nvidia…

Benzinga

Kenvue Stock Is Sliding Today: What's Fueling The Sell-Off?

Shares of Kenvue Inc (NASDAQ:KVUE) are down Monday in anticipation of a negative Trump administration announcement about one of its products.

Benzinga

Trump Administration To Unveil Tylenol-Autism Review, Tout This Drug As Potential Treatment: Report

The Trump administration is expected to unveil new efforts on Monday examining whether one widely used drug may be linked to autism and whether another could help treat it, according to people familiar with the plans who spoke to The Washington Post on condition of anonymity because the announcement was…

Benzinga

Kenvue Pushes To Defend Pain Killer Tylenol Against Autism Claims Ahead Of Government Report

Kenvue Inc. (NYSE:KVUE) interim CEO Kirk Perry met privately this week with Health Secretary Robert F. Kennedy Jr. to argue that there is no proven link between the popular pain reliever Tylenol and autism.

Benzinga

Is Kenvue Stock Underperforming the Dow?

Despite Kenvue’s recent underperformance relative to the Dow, analysts remain moderately optimistic about the stock’s prospects.

Barchart

RFK Jr. To Link Tylenol Use To Autism: Report

Health Secretary Robert F. Kennedy Jr. is preparing to release a report suggesting that the use of a common over-the-counter pain reliever during pregnancy may be tied to a higher risk of autism.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Kenvue Stock Outlook: Is Wall Street Bullish or Bearish?

Kenvue has outpaced the broader market over the past year, and analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Kenvue Stock Has Unusual Put Option Activity After Lower Q2 Sales and CEO Firing

Kenvue, which manufactures Band-Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO had left. Put options are showing unusually high volume today.

Barchart

Kenvue's Q2 2025 Earnings: What to Expect

Kenvue is expected to release its second-quarter earnings next month, and analysts anticipate a double-digit profit dip.

Barchart

Tylenol-Maker Kenvue Launches Turnaround Plans. How Should You Play KVUE Stock Here?

Kenvue Inc ousted its chief executive and announced a strategic review on Monday. Jefferies says KVUE shares could rally to $27.

Get all your
news in one place.

100's of premium titles.
One news app.

Latin Times

Suspect in Fatal Hit-and-Run Killed in a Separate Car Crash Weeks Later

A Texas man accused in a fatal hit-and-run died weeks later in a separate crash that also killed two Good Samaritans, prompting an ongoing investigation.

Barchart

Is Kenvue Stock Outperforming the Nasdaq?

Despite its recent underperformance, Kenvue has outpaced the Nasdaq over the past year, and analysts remain moderately bullish on the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Kenvue Stock Will Climb or Sink?

Kenvue has outpaced the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Kenvue Earnings Preview: What to Expect

Kenvue is set to unveil its Q1 results in the upcoming month, and analysts expect a notable decline in earnings.

MarketBeat

2 Under-the-Radar Consumer Staples Stocks With Big Dividends

Edgewell and Kenvue are under-the-radar consumer staples stocks poised to gain as the U.S. dollar declines. Learn why they may boost your income portfolio.

Barchart

Is Kenvue Stock Outperforming the S&P 500?

Kenvue has outperformed the S&P 500 Index over the past year and analysts remain moderately optimistic about its future outlook.

Barchart

Is Wall Street Bullish or Bearish on Kenvue Stock?

Despite Kenvue trailing the broader market over the past year, Wall Street analysts maintain a moderately bullish outlook on the stock's potential.

1 2 3

People

Robert Eugene Brashers

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.